Physician profile
Ray W Johnson
NPI 1629099072
$3,871.43
in general payments reported to CMS, 2019-2025
25 companies · $476 in 2025
The $476 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $436 · 2021: $273 · 2022: $561 · 2023: $777 · 2024: $706 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $988.14 | 2019-2025 | |
| Merz North America, INC. | $931.88 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $702.51 | 2020-2025 | Blu-U, Odomzo, Ilumya |
| Allergan, INC. | $260.78 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $159.04 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $128.95 | 2022-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $94.09 | 2024-2025 | Bimzelx |
| Sientra, INC. | $57.92 | 2020-2021 | |
| Amgen INC. | $50.27 | 2023 | Otezla, Enbrel |
| Organogenesis INC. | $50.21 | 2023 | Puraply |
| Incyte Corporation | $45.29 | 2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.01 | 2022-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $38.67 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $38.05 | 2020-2021 | |
| Almirall LLC | $34.46 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $33.81 | 2025 | |
| Genentech USA, INC. | $33.40 | 2025 | Xolair |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.72 | 2019-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $29.27 | 2022-2023 | Valchlor |
| Lilly USA, LLC | $25.89 | 2019 | |
| Surgenex LLC | $25.00 | 2025 | Surgraft, Ardeograft, Pellograft |
| E.R. Squibb & Sons, L.L.C. | $22.81 | 2024 | Sotyktu |
| Organon LLC | $21.24 | 2025 | Vtama |
| Dusa Pharmaceuticals, INC. | $14.01 | 2019 | |
| Sandoz INC. | $13.01 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.